open access

Ahead of print
Research Letter
Published online: 2021-03-24
Get Citation

Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis

Milosz J. Jaguszewski, Aleksandra Gasecka, Radoslaw Targonski, Krzysztof J. Filipiak, Lukasz Szarpak
DOI: 10.5603/CJ.a2021.0037
·
Pubmed: 33843036

open access

Ahead of print
Research letters — Clinical cardiology
Published online: 2021-03-24

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

levosimendan; dobutamine; heart failure; intensive care

Supp./Additional Files (1)
Supplementary Digital Content
Download
298KB
About this article
Title

Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis

Journal

Cardiology Journal

Issue

Ahead of print

Article type

Research Letter

Published online

2021-03-24

DOI

10.5603/CJ.a2021.0037

Pubmed

33843036

Keywords

levosimendan
dobutamine
heart failure
intensive care

Authors

Milosz J. Jaguszewski
Aleksandra Gasecka
Radoslaw Targonski
Krzysztof J. Filipiak
Lukasz Szarpak

References (8)
  1. Pathak A, Lebrin M, Vaccaro A, et al. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther. 2013; 38(5): 341–349.
  2. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007; 50(3): 257–263.
  3. Harjola VP, Giannakoulas G, von Lewinski D, et al. Use of levosimendan in acute heart failure. Eur Heart J Suppl. 2018; 20(Suppl I): I2–II10.
  4. Yaman M, Arslan U, Kaya A, et al. Levosimendan accelerates recovery in patients with takotsubo cardiomyopathy. Cardiol J. 2016; 23(6): 610–615.
  5. Bayram M, De Luca L, Massie MB, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005; 96(6A): 47G–58G.
  6. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000; 102(18): 2222–2227.
  7. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5: 13.
  8. Tycińska A, Gierlotka M, Bugajski J, et al. Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society. Kardiol Pol. 2020; 78(7-8): 825–834.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl